Diastolic Perfusion Pressure Predicts Response to Inotropes and Vasopressors and Benefit From Mechanical Circulatory Support in Cardiogenic Shock summary

What is PACUPod: Critical Care?

PACUPod is your trusted source for evidence-based insights tailored to advanced clinical pharmacists and physicians. Each episode dives into the latest primary literature, covering medication-focused studies across critical care and many more. We break down study designs, highlight key findings, and objectively discuss clinical implications—without the hype—so you stay informed and ready to apply new evidence in practice. Whether you’re preparing for board certification or striving for excellence in patient care, PACUPod helps you make sense of the data, one study at a time.

Britany: [excited] Welcome back to PACULit, everyone! Today, we’re diving into a fascinating new study on cardiogenic shock—specifically, how diastolic perfusion pressure can predict response to inotropes and vasopressors, and who might benefit most from mechanical circulatory support. Seth, this one caught my eye immediately. What about you?

Seth: [confident] Absolutely, Britany. Cardiogenic shock remains one of the toughest challenges in acute care, with mortality rates still alarmingly high—over 40 to 50 percent in many cases. So any tool that helps us stratify patients and tailor therapy is a big deal.

Britany: [thoughtful] Right, and the study by Lim and colleagues really zeroes in on that. They focus on diastolic perfusion pressure, or DPP, which is the difference between diastolic arterial pressure and right atrial pressure. It’s a simple hemodynamic parameter but with powerful implications.

Seth: [curious] I love that it’s physiologically grounded. DPP essentially reflects coronary perfusion pressure and systemic microcirculatory flow, which are critical in cardiogenic shock. But before this, we didn’t have a reliable bedside marker to predict who would respond to vasoactive drugs versus who might need early mechanical support like VA-ECMO.

Britany: [excited] Exactly! And that’s the clinical problem here—deciding when to escalate vasoactive drugs and when to jump to mechanical circulatory support. The timing and patient selection have been controversial, with no clear consensus.

Seth: [thoughtful] The heterogeneity of cardiogenic shock patients complicates things. Some have preserved perfusion pressures and respond well to inotropes, while others are refractory and deteriorate rapidly. Identifying those refractory patients early is crucial to improve outcomes.

Britany: [confident] So, the study design is pretty robust. It’s a prospective observational cohort of 93 cardiogenic shock patients, combined with a post hoc subgroup analysis of the randomized ECMO-CS trial. That trial randomized patients to immediate VA-ECMO versus conservative management.

Seth: [curious] And the inclusion criteria were pretty standard—clinical diagnosis of cardiogenic shock with hypotension, elevated filling pressures, and low cardiac output. They didn’t detail exclusions explicitly, but presumably, they followed typical ECMO trial standards.

Britany: [thoughtful] What’s interesting is how they measured the primary physiologic outcome: change in cardiac power output index, or CPOI, after vasoactive escalation. That’s a solid marker of cardiac function improvement.

Seth: [excited] And the results are striking! Vasoactive escalation increased CPOI by an average of 0.23 watts per square meter, which is statistically significant. But here’s the kicker—patients with baseline DPP equal to or above 37 millimeters of mercury had a much better hemodynamic response and lactate clearance.

Britany: [surprised] Twenty percent difference in response between those above and below that DPP cutoff? That’s huge. It suggests DPP can discriminate responders from nonresponders to vasoactive therapy.

Seth: [concerned] On the flip side, patients with DPP below 37 millimeters of mercury showed limited response to vasoactive drugs, indicating a more refractory shock state. That’s clinically important because it tells us who might need early mechanical support.

Britany: [excited] And the post hoc ECMO-CS trial analysis supports this! Patients with DPP less than 37 millimeters of mercury had significantly lower mortality when treated with immediate VA-ECMO. The hazard ratio was 0.37, which means a 63 percent reduction in risk. That’s impressive.

Seth: [thoughtful] Meanwhile, those with DPP above 37 millimeters of mercury didn’t show mortality benefit from early VA-ECMO. So, this parameter could help us avoid unnecessary ECMO in patients likely to respond to vasoactive drugs alone.

Britany: [chuckles] That’s a win-win—better patient outcomes and more efficient resource use. I remember a case in my ICU where we struggled to decide on ECMO timing. Having a simple number like DPP would have been invaluable.

Seth: [laughs] I’ve had similar experiences. Sometimes it feels like we’re flying blind, hoping vasoactives will work before jumping to ECMO. This study gives us a physiologic compass.

Britany: [curious] Seth, what about the secondary outcomes? Did they look at lactate clearance or adverse events?

Seth: [confident] Yes, lactate clearance was better in patients with higher DPP after vasoactive escalation, reinforcing improved perfusion. Adverse events weren’t the primary focus here, but previous ECMO trials highlight bleeding and limb ischemia risks, so patient selection remains key.

Britany: [thoughtful] That aligns with Elsaeidy’s systematic reviews emphasizing ECMO risks and the need for careful patient selection. It’s not just about survival but also quality of life and complications.

Seth: [excited] And the study’s practical takeaway is clear: measure baseline DPP at the bedside to guide therapy. If DPP is below 37 millimeters of mercury, consider early VA-ECMO. If above, escalate vasoactives first.

Britany: [concerned] But we should remember this is a post hoc analysis, so causality isn’t definitive. Prospective validation is needed before changing guidelines.

Seth: [thoughtful] Absolutely. Plus, the cohort size was modest—93 patients—and generalizability might be limited. But it’s a strong hypothesis-generating study.

Britany: [curious] How does this fit with other recent literature? I recall Jeong et al.’s PRECISE score also incorporates perfusion markers to predict mortality in ischemic cardiogenic shock requiring ECMO.

Seth: [confident] Right, Jeong’s work complements this by showing that severe hypoperfusion markers predict higher mortality despite ECMO. So, combining DPP with other scores might refine risk stratification further.

Britany: [excited] And Piccone’s 2024 review on ECMO highlights both benefits and complications, reinforcing the need for precise patient selection. This study adds a valuable piece to that puzzle.

Seth: [thoughtful] Hamzaoui’s recommendations for hemodynamic monitoring also support measuring diastolic pressure and pulse pressure in cardiogenic shock management. DPP fits perfectly into that framework.

Britany: [laughs] You know, Seth, this reminds me of when we tried to titrate vasopressors in a patient with borderline pressures. We were guessing, and the patient ended up needing ECMO anyway. If only we had DPP data back then!

Seth: [chuckles] Well, hindsight is 20/20. But that’s why these studies matter—they turn guesswork into evidence-based decisions.

Britany: [excited] So, to summarize, DPP is emerging as a simple, physiologically sound marker that predicts who will respond to vasoactive drugs and who benefits from early mechanical support in cardiogenic shock.

Seth: [confident] Exactly. It’s about individualizing therapy—avoiding futile escalation of vasoactives in refractory patients and preventing unnecessary ECMO in responders.

Britany: [thoughtful] And future directions? The authors suggest prospective validation and integration with biomarkers to optimize timing and selection for mechanical support.

Seth: [curious] That would be a game changer. Imagine combining DPP with lactate trends, biomarkers like NT-proBNP, and echocardiographic data to create a comprehensive shock profile.

Britany: [excited] That’s precision medicine in critical care! Before we wrap up, any clinical pearls you want to share?

Seth: [laughs] Just that measuring right atrial pressure and diastolic arterial pressure routinely in shock patients can be more informative than we realize. It’s not just numbers—it’s about understanding the patient’s coronary and systemic perfusion.

Britany: [chuckles] And don’t forget to consider the whole clinical picture—hemodynamics, labs, and patient trajectory. DPP is a tool, not a standalone answer.

Seth: [confident] Well said. This study gives us a new lens to view cardiogenic shock management. I’m excited to see how it influences practice.

Britany: [excited] Me too! Thanks for the great discussion, Seth. And thanks to all our listeners for tuning in to PACULit. Don’t forget to check out the full article by Lim et al. in Circulation: Heart Failure, 2025.

Seth: [professional] Thanks, Britany. Always a pleasure to dissect cutting-edge literature with you. Until next time, stay curious and keep pushing the boundaries of clinical care.

Britany: [relieved] That’s a wrap! Stay safe, everyone, and keep those DPPs in mind. Bye for now!

Seth: [laughs] Bye!